Week in Review: China's Neusoft Raises $610 Million for Life Science Subsidiaries

Neusoft, a China software and medical device company, raised $610 million from investors to support its medical imaging and mobile health divisions; SciClone Pharma in-licensed China marketing rights to two cardiovascular drugs from The Medicines Company in a deal worth up to $50.5 million; Weijian Pharma obtained China marketing rights to an infertility treatment produced by LG Lifesciences of Korea; China has made the most patent filings in the world in each of the past few years, many of them in life science; an Ebola vaccine, developed jointly by China's Academy of Military Medical Sciences and Tianjin CanSino Biotech, has been approved to begin clinical trials; Hutchison MediPharma dosed the first patient in a China Phase III clinical trial of cancer drug fruquintinib; Ypsomed, a Swiss medical device maker, signed a CMO agreement with a Suzhou company to make injection pens for China diabetes patients; and China Pioneer Pharma will offer NeutroPhase, a topical antimicrobial product, free of charge to China patients with flesh-eating disease. More details.... Stock Symbols: (SHA: 600718) (NSDQ: SCLN) (NSDQ: MDCO) (AIM: HCM) (HK: 1345) Share this with colleagues: // //